Physician profile
Christopher Rhee
NPI 1750365961
$3,391.89
in general payments reported to CMS, 2019-2025
24 companies · $561 in 2025
The $561 reported for 2025 was more than what 75% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $203 · 2021: $178 · 2022: $330 · 2023: $826 · 2024: $668 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,055.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $506.42 | 2019-2024 | |
| Janssen Biotech, INC. | $469.95 | 2022-2025 | Stelara, Tremfya |
| Genzyme Corporation | $378.20 | 2022-2025 | |
| Mirum Pharmaceuticals, INC. | $356.31 | 2022-2025 | Livmarli |
| Qol Medical, LLC | $268.07 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $254.42 | 2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $172.58 | 2021-2025 | Gattex, Eohilia |
| Travere Therapeutics, INC. | $167.93 | 2019-2023 | Cholbam |
| Cook Medical LLC | $133.24 | 2019 | |
| Alexion Pharmaceuticals, INC. | $131.97 | 2019 | |
| Aimmune Therapeutics, INC. | $110.11 | 2025 | Zenpep |
| Neuraxis, INC. | $76.06 | 2024 | |
| Nestle Healthcare Nutrition INC. | $69.79 | 2022 | |
| Sandoz INC. | $69.47 | 2023-2024 | Hyrimoz |
| Albireo Pharma, INC. | $45.04 | 2023 | Bylvay |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $31.07 | 2025 | Smoflipid |
| Amgen INC. | $24.67 | 2023 | Amjevita |
| Ipsen Biopharmaceuticals, INC | $23.84 | 2023 | Bylvay |
| Argon Medical Devices, INC. | $19.55 | 2022 | |
| Celltrion USA INC. | $19.09 | 2025 | Vegzelma |
| Applied Medical Technology INC | $17.61 | 2019 | |
| Evoendo, INC | $17.06 | 2023 | |
| Intra-Sana Laboratories | $15.63 | 2021 | |
| Pfizer INC. | $13.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rhee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.